Intravitreal implant Iluvien has been approved for use in UK patients for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

The rubber stamp follows two, three-year double-masked, prospective sham-controlled studies in 282 patients with NIU-PS, both of which showed the steroid injection to be effective.

The drug’s producer Alimera Sciences said it was now working closely with all stakeholders to ensure eligible patients with NIU-PS in the UK could benefit from the treatment as soon as possible.